U.S. Stock Markets End Mixed On Tuesday, July 8, 2025
- Published Jul 08, 2025
- Market News

The U.S. equity markets concluded Tuesday’s session with a mixed tone as investors weighed renewed tariff anxieties and shifting macroeconomic signals. The S&P 500 edged lower by 4.46 points (0.1%) to close at 6,225.52, while the Dow Jones Industrial Average dropped 165.60 points (0.4%) to 44,240.76. The Nasdaq Composite managed a modest gain, rising 5.95 points to 20,418.46, reflecting resilience in select technology names. The Russell 2000 index of small-cap stocks rose 14.51 points (0.7%) to 2,228.74, outperforming its large-cap peers despite the broader risk-off environment.
Macroeconomic Reports
Macroeconomic data on Tuesday reflected a cautious outlook. A Federal Reserve Bank of Dallas study indicated that recent immigration restrictions and deportation measures could trim U.S. GDP growth by nearly a full percentage point in 2025, with economists now projecting annual growth to cool to 1.5%, down from close to 3% in previous years. The policy shift is also expected to nudge inflation slightly higher this year.
S&P 500, Dow 30, Nasdaq, and Russell Index Highlights
-
S&P 500: Down 0.1% to 6,225.52.
-
Dow 30: Down 0.4% to 44,240.76.
-
Nasdaq: Up less than 0.1% to 20,418.46.
-
Russell 2000: Up 0.7% to 2,228.74.
Key Stock Highlights
NVIDIA (NVDA)
NVIDIA shares remained resilient despite mounting pressure from new U.S. trade restrictions, including expanded tariffs and tighter AI chip export controls. The stock recently hit an all-time high, buoyed by robust AI demand and positive analyst commentary. Citi raised its price target, citing a growing addressable market and strong sovereign AI demand, which could drive billions in revenue in 2025. The company’s Blackwell chip ramp-up continues smoothly, alleviating earlier supply concerns.
Tesla (TSLA)
Tesla shares endured a sharp decline, falling nearly 7% as CEO Elon Musk announced the formation of a new political party, the “America Party.” This move reignited investor concerns about Musk’s focus and leadership at a time when Tesla is already grappling with declining vehicle deliveries and narrowing margins. Year-to-date, Tesla stock is down 22.5% and now trades 38.5% below its December 2024 peak.
Oracle (ORCL)
Oracle shares slipped 2.1%, underperforming the broader market, as investors rotated out of technology stocks amid tariff uncertainty. The company continues to face headwinds from shifting global trade dynamics.
Tariffs and Trade Developments
Tariff uncertainty dominated market sentiment after President Trump postponed the implementation of reciprocal tariffs from July 9 to August 1. Letters sent to 14 countries outlined potential import duties ranging from 25% to 40%, with additional levies possible for BRICS nations. The market remains focused on whether ongoing negotiations can defuse trade tensions before the new deadline. The delay adds complexity for the Federal Reserve as it assesses inflation risks and for retailers preparing for the holiday season.
Yield Curve and Interest Rates
Treasury yields climbed, with the benchmark 10-year note rising to 4.396%. Investors braced for the impact of upcoming government debt auctions and the potential inflationary effects of new tariffs.
Vista Partners Watchlist Highlights & Updates

-
HC Wainwright: Initiated Covrage on EPRX with a “Strong Buy” on June 26, 2025.
-
Canaccord Genuity: Initiated coverage with a “Speculative Buy” rating in June 2025.
-
Raymond James Ltd.: Maintains a “Strong Buy” rating as of June 2025, with a history of upgrades from “Outperform” to “Strong Buy” over the past year.
-
Research Capital Corporation: Maintains a “Buy” rating, consistently reaffirming its positive stance throughout 2024 and 2025.
Eupraxia announced on July 8 that the first patient dosed in their Phase 2b randomized, placebo-controlled portion of the RESOLVE clinical trial evaluating EP-104GI, an investigational treatment for eosinophilic esophagitis (“EoE”). EP-104GI is injected directly into the affected tissues of the esophagus to reduce inflammation with stable, localized, and long-duration drug delivery, while minimizing unwanted systemic adverse events and side effects often associated with steroid-based therapies. The Phase 2b portion of the RESOLVE study will enroll a minimum of 60 participants randomized in a 1:1:1 ratio to receive one of two doses of EP-104GI or placebo. After six months, eligible patients initially dosed with placebo may elect to receive EP-104GI. The primary objective is to assess the efficacy of EP-104GI in improving tissue health, as measured by the Eosinophilic Esophagitis Histology Scoring System (“EoEHSS”). Secondary and exploratory objectives include evaluating symptomatic improvement through patient-reported outcomes — Straumann Dysphagia Index score (SDI) and Dysphagia Symptom Questionnaire (DSQ), endoscopic and histologic changes (including Peak Eosinophil Count, “PEC”), pharmacokinetics, safety, and tolerability of the selected dose regimens. Up to 25 sites globally are expected to participate in the trial.The Phase 2b portion of the study employs an innovative adaptive design to select the doses of EP-104GI that are administered to patients. The first active dose selection was based on available data from cohorts 1 to 8 of the Phase 2a portion of the study. Based on the previously reported safety, pharmacokinetic, and efficacy data from cohorts 1 to 6, and additional one month data from cohorts 7 and 8, the 120 mg dose (20 injections of 6 mg per site) from cohort 8 was selected for the first treatment arm in the dose optimization phase. A second dose will be selected for evaluation after enrollment in the first arm is complete, based on additional long-term data from the Phase 2a portion of the study. James Helliwell, CEO of Eupraxia Pharmaceuticals stated, “Entering into the Phase 2b stage of the RESOLVE trial is a significant event for Eupraxia. This is an important step for us before proceeding towards the pivotal trials necessary for submitting an application for regulatory approval. We are optimistic that EP-104GI has the potential to significantly advance the standard of care and offer a meaningful new treatment paradigm for patients living with EoE.”





Shares of ADT Inc. (ADT) is a leading provider of monitored security and automation solutions for residential and small business customers in the United States and Canada.
ADT released Q1, 2025 results on Thursday, April 24 and highlighted the following: Continued strong financial results with record recurring monthly revenue and customer retention, GAAP operating cash flows up 28%, Adjusted Free Cash Flow including interest rate swaps up 105%, Returned $445 million to shareholders through share repurchases and dividends, and that they are on track to achieve full year 2025 guidance metrics.
On April 30, ADT in collaboration with Yale and the Z-Wave Alliance, announced the launch of the Yale Assure Lock 2 Touch with Z-Wave for ADT+. The Z-Wave 800 Series smart lock is the only one on the market with fingerprint control and the first smart lock to leverage the newly introduced Z-Wave User Credential Command Class. This industry-first innovation allows users to unlock and disarm their ADT+ security system using just their fingerprint.On Jan. 22, ADT announced the appointment of Thomas Gartland to the Company’s Board of Directors as an additional independent director. In conjunction with his appointment, Gartland will join the Board’s Audit Committee. Gartland is chairman and chief executive officer of Montway Auto Transport, a privately held auto transport company, and has held this position since 2023. Prior to Montway, Gartland served as executive chairman of Scan Global Logistics and as president, North America, for Avis Budget Group. Gartland serves on the boards of Xenia Hotels & Resorts, Inc. and ABM.




Quote of the Day
“People only see what they are prepared to see.” – Ralph Waldo Emerson
Investing & Inspiration
“We cannot live only for ourselves. A thousand fibers connect us with our fellow men.” – Herman Melville
Post View Count : 501